Blank, Patricia; Filipits, Martin; Dubsky, Peter; … - In: PharmacoEconomics 33 (2015) 2, pp. 179-190
Our study suggests that molecular markers can be sensibly combined with clinical guidelines to determine the risk profile of adjuvant breast cancer patients. Compared with the current German best practice (German-S3), combinations of EPclin with the St. Gallen, German-S3 or NCCN guideline and...